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stenosis, 1 duodenal stenosis). Biliary lithiasis was observed in 5 patients (9.8%),
whereas 1 developed a post-transplantation, drug-induced pancreatitis. No bilio-
pancreatic malformations were detected in 33 patients (64.6%); a family history of
chronic pancreatitis was observed in 43.3% of them. Furthermore, genetic analysis
showed mutations in CFTR, SPINK1 and PRSS1 genes in 31%, 7.7% and 3.6%
of patients, respectively. The sweat test identiﬁed border-line values in 23.3% of
patients, allowing a diagnosis of atypical CF.
Conclusions: In 33 pediatric patients affected by RIP we observed high percentages
of familial/hereditary pancreatitis (43.3%) and atypical CF (23.3%). Genetic testing
conﬁrmed the high frequency of CFTR mutations and has been reported to be useful
in the detection of atypical forms of CF. An early diagnosis of atypical CF allows
a better quality of life and prognosis.
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Case: A 28-year-old female cystic ﬁbrosis (CF) patient (R334W/852del22) came to
our CF referral Center in 1994. She presented with symptoms of prolonged acute
respiratory infections and recurrent episodes of pneumonia, and was treated with
ciproﬂoxacin and aminoglycosides. Sputum swabs samples were cultured and airway
colonization with Pseudomonas aeruginosa and Staphylococcua aureus was diag-
nosed. Pulmonary function tests documented a decrease in the mid-maximal ﬂow
rate, reﬂecting small airways obstruction and the mean forced expiratory volume in
1 sec value was 46% of predicted. Restrictive changes, characterized by declining
total lung capacity and vital capacity were also observed. Computed tomography
(CT) images of the chest showed that airway and parenchymal changes were present
throughout both lungs. Multiple areas of extensive bronchiectasis, atelectasis, mucus
plugging and defects of pulmonary vessels perfusion were seen in the left upper
lobe and in the right lower lobe. The patient required several hospital admissions for
pulmonary exacerbations and was regularly examinated at 2-month intervals. Her
CF was complicated by renal insufﬁciency (serum creatinine levels 4.4mg/dl) which
required long-term dialysis therapy. In March 2004 she underwent live-related donor
renal transplant and started an immunosuppressive therapy with cyclosporine. CT
images taken two years after transplantation documented a signiﬁcant size reduction
of bronchiectasis in the upper left lobe and a complete regression of atelectasis and
bronchiectasis in the lower right lobe. There were also signs of pulmonary perfusion
improvement in both lungs. The patient had lower mean serum creatinine values and
regained the weight lost during dialysis. Her pulmonary function improved from
46% predicted to 65% predicted. Since transplantation, she did not require any
hospitalization for pulmonary exacerbations and the interval between routine visits
was lengthened. This case highlights the fact that renal transplantation associated
with cyclosporine treatment may have beneﬁcial effect in terms of improvement of
lung damage progression in CF patient with renal failure. We also suggest that a
multicentric study may be proposed to treat with cyclosporine patients affected by
CF pulmonary disease.
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Introduction: The aim of this research has been to study the efﬁcacy of the
telemonitoring-assistance-therapy in Cystic Fibrosis patients, comparing it to the
standard medical care and therapy. We compared the homemade spirometry data
obtained by a monitoring system given to the CF patient and sent to a Data Centre,
using a telephone connection, with those made in our medical ambulatory, during
a clinical control.
Methods: For this demonstration we studied the values of FEV1 and PEF of 18 CF
patients. The ﬁrst spirometry, with following transmission, has been made during the
medical control in our ambulatory at the time of enrolment. All the used instruments
have been set according to the ATS standardisation. The data have been collected
using the Filemaker-Pro-7 database and elaborated with the software EPI-Info 6.00.
The t-student test has been used to assess the data with a p-value <0.05.
Results: From the ﬁrst data it seems that, for many patients, the examined
spirometry values are higher in the ambulatory made tests than in the homemade
ones, obtained without any medical control. The comparison among the average of
FEV1 does not show any statistically difference between the two groups (t = 0.9711,
pvalue = 0.3412). Those patients that precisely followed with care the protocol of the
study, at the end obtained similar spirometry as at home as at the FPR ambulatory.
A further conﬁrmation of this consideration comes from the comparison of PEF
values that is statistically signiﬁcant (t = 2.3415 p = 0.0278). This means that the
collaboration of the patient is different at home from the one offered in the
ambulatory.
Conclusions: In conclusion we can state that the medical control is useful to
perform the spirometry but with the acquisition, along the time, of the homemade
telemonitoring know-how, the patient becomes less dependent from the medical
presence and instructions.
P50 ATYPCAL CYSTIC FIBROSIS (ACF): AN EXPERIENCE OF A
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Introduction: During last decade an increased number of patients (pts) have been
diagnosed as ACF. According to the consensus opinion (Thorax 2006;61:627–635)
searching for ACF should start with sweat test (ST) in presence of suggestive
symptoms. If the ST is normal or border-line, a panel of at least 31 mutations
may help to diagnose ACF. A complete genetic analysis (GA) is indicated when
only one mutation is detected. Abnormal bioelectrical properties of nasal/intestinal
epithelium have to be performed in controversial cases.
Aim: To describe clinical and laboratory ﬁndings compatible with ACF in a cohort
of paediatric population followed at a CF Center.
Patients and Methods: CF Database data of 180 pts aged 1−18 years (y) identiﬁed
by symptoms after 1990 at Care Center were retrospectively reviewed. Inclusion
criteria for ACF were: sweat chloride level (SCL) < 60 mEq/l, clinical manifesta-
tions suggestive of CF at ﬁrst visit, two mutations or one mutation/polyT5/12TG
variant on both alleles by GA. 6 pts were ruled out despite suggestive symptoms
and ST <60mEq/l, because of only one detected mutation and so classiﬁed as
“CFTRpathies-correlated”. GA was based on a two level approach, as a ﬁrst analysis
of 31 mutations by ASO dot-blot followed by the scanning of the whole gene by
direct sequencing.
Results: Based on clinical ﬁndings, ST and GA 9 pts (4M, mean age at diagnosis
6.7 y, 18m-15y) were enrolled. All pts had pancreatic sufﬁciency (PS); mean value
of ﬁrst FEV1 (5/9) was 100, 3% with no PA colonization. 2/9 had pancreatitis
(PT) as ﬁrst manifestation. Mean value of SCL was 38.9 (24−50). 4/9 had severe
mutation/polymorphism (PolyT5/12TG).
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M 13 RRI,P 39 N1303K/D1152H HI 77 + B/P S,P
F 18m FTT,RRI 42.5 DF508/5T NP + B/P N
M 22m FTT,F 38 DF508/5T SA + B/P S
F 2.8 FTT,RRI 31 DF508/5T-9T NP + B/P NMH
F 15 RRI 46 W1282X/D1152H SA 97.6 + B/P NMH,S
M 11 PT 50 DF508/D1152H NP 97 + N N
F 4 RRI 34 D1152H/D1152H HI + B N
M 6 PT 24 E193/2997F HI 106 + B/P N
F 5.4 F,RRI 46 G542X/5T-9T SA 124 + B/P NMH
Legend: RRI recurrent respiratory infections; FTT failure to thrive; P polyps; S
sinusitis; F familiarity; HI Haemophilus Inﬂuentiae; SA Staphylococcus Aureus; PA
Pseudomonas Aeruginosa; B/P bronchitis/peribronchitis; NMH nasal mucosal hyper-
trophy; NP non pathogens; N negative.
Conclusions: Based on frequency of ACF diagnosis in adults, ACF should be
assessed also in children with suggestive symptoms of CF by SCL and GA.
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Introduction: Many Authors observed that cystic ﬁbrosis (CF) patients often are
at risk of fractures. Our aim was to establish factors involved in bone disease in
CF.
Methods: We enrolled 21 patients affected by CF (15 F and 6 M, age range 11−42
years). They have been distinguished for age, sex, respiratory function, pancreatic
function, serum calcium levels, 25OH vitD, PCR, T score and Z score, and DXA
scores. BMD Evaluation: Normal (T score between + 1 and −1), Osteopenia (T score
